Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.31 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19722409 | 0.96 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL19722382 | 0.92 | CYP2C9 (0.31) | CYP2C9ALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL19722071 | 0.90 | CYP2C9 (0.33) | CYP2C9ALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL19722406 | 0.90 | CYP2C9 (0.33) | CYP2C9ALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL19722394 | 0.89 | OPRL1 (0.34) | CYP2C9ALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL19722175 | 0.87 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPTS1PR1 | |
| SCHEMBL19722571 | 0.86 | CYP2C9 (0.33) | CYP2C9ALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL19721885 | 0.86 | CYP2C9 (0.33) | CYP2C9ALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL19722115 | 0.86 | CYP2C9 (0.33) | CYP2C9ALDH1A1LMNAMAPTOPRL1 | |
| SCHEMBL19722361 | 0.85 | CYP2C9 (0.42) | CYP2C9ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | JNC CORPORATION (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2017-12-28 | — | — | US | disclosed |
| EP-3257839-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2017-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | SP1, HVCN1, CXCR1 | CYP2C9 4226/4885ALDH1A1 3882/4885LMNA 1014/4885 |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | SP1, SPIN1, SAV1 | CYP2C9 4442/4885ALDH1A1 3267/4885LMNA 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.